Posters

    Characterization of Aerosol Exposure, Metabolism and Pharmacokinetics for Toxicological Assessment Using In Vitro Organotypical Airway Models

    Knorr, A.; Dutertre, Q.; Rhouma, M.; Martin, E.; Almstetter, M.; Majeed, S.; Mathis, C.; Frentzel, S.; Bentley, M.; Hoeng, J.; Vanscheeuwijck, P.; Peitsch, M. C.

    Conference date
    Jun 5, 2016
    Conference name
    The 64th ASMS Conference
    Link to more information
    Topic
    Summary

    Direct exposure to inhaled mainstream cigarette smoke is known to cause smoking-related damage in the human lung. Aerosol exposure of human three dimensional (3D) organotypical airway epithelial tissue cultures, growing at an air-liquid interface, is a well-established in vitro model enabling a Systems Biology-based Reduced Risk Product (RRP) assessment. Migration kinetics and metabolism of deposited aerosol compounds are important parameters in understanding their bioavailability. To better understand the role of xenobiotic metabolism after cigarette smoking, human subcellular liver and lung fraction models (microsomes, S9) have been established to assess metabolite profiles and reactive metabolites relevant for toxicological assessment. The integration of exposure characterization results with a systems toxicology approach to measure the biological impact of exposure is informative to the product assessment strategy and has the potential to highlight modes of action associated with RRP exposure. 

    Related Publications

    Systems Toxicology Assessment of Aerosol from a Candidate Modified Risk Tobacco Product Compared with Cigarette Smoke on Organotypic Gingival Epithelial Cultures

    Aerosol Chemistry Systems Toxicology

    Screening Of Aqueous Media Using GC×GC-TOF-MS

    Aerosol Chemistry Systems Toxicology

    In Vitro Test Systems for Aerosols Toxicology Assessment - Characterization of Exposure, Metabolism and Kinetics

    Aerosol Chemistry Systems Toxicology

    Applicability of Different Soft Nucleophiles for the Screening of Reactive Metabolites upon Microsomal Activation of Furan Mixtures and Cigarette Smoke

    Aerosol Chemistry Systems Toxicology

    Assessment of Mitochondrial Function Following Long-Term Treatment of Human Bronchial Epithelial Cells with Total Particulate Matter from a candidate Modified-Risk Tobacco Product versus Cigarettes

    Aerosol Chemistry Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.